infliximab   Click here for help

GtoPdb Ligand ID: 5004

Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650 | Zymfentra® (subcutaneous formulation)
Approved drug Immunopharmacology Ligand
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
infliximab-dyyb; CT-P13Remsima; Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agent[1-2,8]
infliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agent 
infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agent[3]
NI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent 
BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis 
Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritis 
infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agent 
STI-002 MabTech/Sorrento Therapeutic   
Infliximab biosimilar 1 Nippon KayakuApproved (Japan 2014)As per reference agent
Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

No information available.
Summary of Clinical Use Click here for help
Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [7] and ulcerative colitis. A subcutaneous formulation is available for use as maintenance option for patients with Crohn's disease/ulcerative colitis following intravenously infliximab therapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Infliximab binds with high affinity to soluble and transmembrane forms of TNFα thereby inhibiting its binding with its receptors, leading to a decrease in the production of proinflammatory cytokines.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)